Letter by Moris and Avgerinos Regarding Article, “Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with great interest the recent publication of Hong et al1 evaluating the potential superiority of clopidogrel plus aspirin versus aspirin alone in terms of recurrent cerebral ischemia prevention in patients with acute ischemic stroke caused by large artery atherosclerosis. The striking finding of this trial was that clopidogrel plus aspirin might not be superior to aspirin alone to prevent new ischemic lesion and clinical vascular events in patients with acute ischemic stroke caused by large artery atherosclerosis.1 Moreover, they found that overall 35.2% of patients had ischemic lesion recurrence within 30 days: the rate of 36.5% in the clopidogrel plus aspirin arm was higher than expected and that of 35.9% in the aspirin-alone arm was lower than …